Chief Executive Officer (formerly President and COO) · Compass Therapeutics, Inc. (CMPX)

Vered Bisker-Leib

A named executive officer of Compass Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$4,067,284

Salary $500,000Stock awards $1,572,000Bonus $202,500

FY2022: $1,724,739

2nd of 2 named executive officers at Compass Therapeutics by FY2023 total.

2 named officers on file for Compass Therapeutics, FY2023

Vered Bisker-Leib’s pay file — $29

  • 5 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Compass Therapeutics’s whole pay program stands against its peers

  • Compass Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CMPX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2024 (DEF 14A).

Free

Get Vered Bisker-Leib’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Vered Bisker-Leib compensation by year

Compass Therapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as Compass Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023
Salary$325,000$360,000$400,000$475,000$500,000
Bonus$160,875$160,000$320,000$320,000$202,500
Stock awards$569,159$0$2,298,000$0$1,572,000
Option awards$0$2,051,579$1,432,000$918,306$1,776,284
Non-equity incentive$0$0$0$0$0
Pension and deferred compensation$0$0$0$0$0
All other$0$0$0$11,433$16,500
Total$1,055,034$2,571,579$4,450,000$1,724,739$4,067,284

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Compass Therapeutics, Inc. DEF 14A filed April 29, 2024, accession 0001140361-24-022700, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Compass Therapeutics, Inc. filed document, accession 0001140361-24-022700. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.

$1.1M
$2.6M
$4.5M
$1.7M
$4.1M
FY19
FY20
FY21
FY22
FY23
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU400,000$624,000—
RSU300,000$468,000—
Option475,000—$3.93
Option270,826—$2.40
Option116,652—$5.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Compass Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Compass Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Thomas SchuetzPresident of Research & Development (formerly CEO)$4,873,206
Vered Bisker-Leib · this pageChief Executive Officer (formerly President and COO)$4,067,284

Board service

Compass Therapeutics board · FY2023

How this board is paid

Company policy: Compass Therapeutics pays directors a $45,000 cash retainer. As stated in Compass Therapeutics's FY2023 proxy.

The full Compass Therapeutics compensation record

free company brief

This page is one person within Compass Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Compass Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Vered Bisker-Leib's compensation dossier · One-time report. No refunds.